Terri Sebree - Zynerba Pharmaceuticals President
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
President
Ms. Terri B. Sebree serves as President of the company. Prior to joining our company, Terri B. Sebree has served as our president since October 2014. Prior to joining our company, Ms. Sebree served as our business consultant from May 2014 to October 2014. Ms. Sebree has more than 30 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, Ms. Sebree served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. Ms. Sebree currently serves on the board of directors of Serodus ASA, a publicly traded company on the Oslo Stock Exchange since 2014.
| Age | 65 |
| Tenure | 10 years |
| Phone | 484 581 7505 |
| Web | https://www.zynerba.com |
Zynerba Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4511) % which means that it has lost $0.4511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8713) %, meaning that it created substantial loss on money invested by shareholders. Zynerba Pharmaceuticals' management efficiency ratios could be used to measure how well Zynerba Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Zynerba Pharmaceuticals currently holds 334.43 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Zynerba Pharmaceuticals has a current ratio of 6.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zynerba Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| John Bardi | Intracellular Th | N/A | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Adam Havey | Emergent Biosolutions | 53 | |
| Katherine Strei | Emergent Biosolutions | 62 | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Rob Aukerman | Phibro Animal Health | 66 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Mark Neumann | Intracellular Th | 61 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Robert Davis | Intracellular Th | 73 | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Jonathan Bendheim | Phibro Animal Health | 48 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| John Condon | Intracellular Th | N/A | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Atul Saran | Emergent Biosolutions | 51 | |
| Sean Kirk | Emergent Biosolutions | 45 | |
Management Performance
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 |
Zynerba Pharmaceuticals Leadership Team
Elected by the shareholders, the Zynerba Pharmaceuticals' board of directors comprises two types of representatives: Zynerba Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zynerba. The board's role is to monitor Zynerba Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zynerba Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zynerba Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Fickenscher, CFO, Vice President - Corporate Development | ||
| Albert II, Chief Sec | ||
| Armando MBA, Chairman CEO | ||
| Joseph Apostolico, VP HR | ||
| Terri Sebree, President |
Zynerba Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zynerba Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |